Literature DB >> 9829013

Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders.

D A Regier1, D S Rae, W E Narrow, C T Kaelber, A F Schatzberg.   

Abstract

BACKGROUND: The co-occurrence of anxiety disorders with other mental, addictive, and physical disorders has important implications for treatment and for prediction of clinical course and associated morbidity.
METHOD: Cross-sectional and prospective data on 20,291 individuals from the Epidemiologic Catchment Area (ECA) study were analysed to determine one-month, current disorders, one-year incidence, and one-year and lifetime prevalence of anxiety, mood, and addictive disorders, and to identify the onset and offset of disorders within the one-year prospective period.
RESULTS: Nearly half (47.2%) of those meeting lifetime criteria for major depression also have met criteria for a comorbid anxiety disorder. The average age of onset of any lifetime anxiety disorder (16.4 years) and social phobia (11.6 years) among those with major depression was much younger than the onset age for major depression (23.2 years) and panic disorder.
CONCLUSIONS: Anxiety disorders, especially social and simple phobias, appear to have an early onset in adolescence with potentially severe consequences, predisposing those affected to greater vulnerability to major depression and addictive disorders.

Entities:  

Mesh:

Year:  1998        PMID: 9829013

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  76 in total

Review 1.  Burden of anxiety disorders in pediatric medical settings: prevalence, phenomenology, and a research agenda.

Authors:  Holly J Ramsawh; Denise A Chavira; Murray B Stein
Journal:  Arch Pediatr Adolesc Med       Date:  2010-10

2.  False beliefs: the current treatment of patients with depression.

Authors:  Yves Lecrubier
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

3.  Substance use disorders in individuals with body dysmorphic disorder.

Authors:  Jon E Grant; William Menard; Maria E Pagano; Christina Fay; Katharine A Phillips
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

4.  Integrating evidence-based assessment into clinical practice for pediatric anxiety disorders.

Authors:  Joseph F McGuire; Nicole E Caporino; Sophie A Palitz; Philip C Kendall; Anne Marie Albano; Golda S Ginsburg; Boris Birmaher; John T Walkup; John Piacentini
Journal:  Depress Anxiety       Date:  2019-06-24       Impact factor: 6.505

5.  The long-term treatment outcomes of depression and anxiety comorbid with substance abuse.

Authors:  G Bovasso
Journal:  J Behav Health Serv Res       Date:  2001-02       Impact factor: 1.505

6.  Anxiolytic effects of Lippia citriodora in a mouce model of anxiety.

Authors:  Atousa Bonyani; Seyed Ebrahim Sajjadi; Mohammad Rabbani
Journal:  Res Pharm Sci       Date:  2018-06

Review 7.  Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes.

Authors:  Kiersten S Smith; Uwe Rudolph
Journal:  Neuropharmacology       Date:  2011-07-27       Impact factor: 5.250

8.  Genetic and environmental influences on the co-morbidity between depression, panic disorder, agoraphobia, and social phobia: a twin study.

Authors:  Miriam A Mosing; Scott D Gordon; Sarah E Medland; Dixie J Statham; Elliot C Nelson; Andrew C Heath; Nicholas G Martin; Naomi R Wray
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

9.  Integrating structural and epidemiological research to inform the classification of psychopathology.

Authors:  Ayelet Meron Ruscio
Journal:  Int J Methods Psychiatr Res       Date:  2009-12       Impact factor: 4.035

Review 10.  Refinement of diagnosis and disease classification in psychiatry.

Authors:  Yves Lecrubier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.